On July 7, 2025, Apogee Therapeutics, Inc. reported positive 16-week results from its Phase 2 APEX trial for the anti-IL-13 antibody, APG777, showing a 71% EASI reduction compared to 34% with placebo, along with their first patient dosing for a comparative trial against DUPIXENT.